Ramesh Prajith Raj, Krishnan Priya, Prabu Samyuktha, Srinivasan Varshini, Niranjan Varalakshmi
Department of Gastroenterology and Hepatology, Mayo Clinic, 1216 2nd St SW, Rochester, MN, 55902, USA.
Department of Medicine, University of Louisville, Chief of Medicine, RRVAMC, University of Louisville, 550 South Jackson Street, 3rd Floor, Ste. A3K00, Louisville, KY, 40202, USA.
Obes Pillars. 2024 Oct 10;12:100142. doi: 10.1016/j.obpill.2024.100142. eCollection 2024 Dec.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed as nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of obesity and metabolic syndrome. It is mainly caused by insulin resistance. With the increased risk of visceral obesity in South Asians, the prevalence of MASLD is on the rise. The morbidity associated with MASLD and its complications, including hepatocellular carcinoma is projected to increase in this South Asian population.
In this narrative review we explore the diagnosis and management of MASLD in the South Asian population. We summarize the findings from the recent literature on the diagnostic methods and management options for MASLD in this population.
Through our search we found no specific guidelines for the diagnosis and management of MASLD in the South Asian population. The existing general guidelines may not be applied to South Asian populations due to the differences in phenotype, genotype, social and cultural aspects. South Asian countries also have limited resources with the non-availability of newer pharmacotherapeutic agents.
The goal of this review is to guide obesity physicians and primary care providers to have a stepwise approach to treat patients at risk for MASLD with a main focus on interdisciplinary management most applicable to South Asian patients. More research is needed to formulate guidelines and algorithm that are specific for the South Asian population.
代谢功能障碍相关脂肪性肝病(MASLD),以前称为非酒精性脂肪性肝病(NAFLD),是肥胖和代谢综合征的肝脏表现。它主要由胰岛素抵抗引起。随着南亚人内脏肥胖风险的增加,MASLD的患病率正在上升。预计在这个南亚人群中,与MASLD及其并发症(包括肝细胞癌)相关的发病率将会增加。
在这篇叙述性综述中,我们探讨了南亚人群中MASLD的诊断和管理。我们总结了近期关于该人群MASLD诊断方法和管理选择的文献研究结果。
通过检索,我们发现没有针对南亚人群MASLD诊断和管理的具体指南。由于表型、基因型、社会和文化方面的差异,现有的一般指南可能不适用于南亚人群。南亚国家资源有限,缺乏更新的药物治疗剂。
本综述的目的是指导肥胖症医生和初级保健提供者采用逐步方法治疗有MASLD风险的患者,主要侧重于最适用于南亚患者的跨学科管理。需要更多的研究来制定针对南亚人群的指南和算法。